AI assistant
Chemomab Therapeutics Ltd. — Director's Dealing 2021
Mar 18, 2021
35107_dirs_2021-03-18_fe276430-6be5-439a-926c-689a225fb201.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Chemomab Therapeutics Ltd. (CMMB)
CIK: 0001534248
Period of Report: 2021-03-16
Reporting Person: THIEL PETER (10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| American Depositary Shares | 877973 | Indirect |
Footnotes
F1: Received in exchange for 34,129 Preferred B Shares and 34,130 Preferred C Shares of Chemomab Ltd. in connection with the merger of Chemomab Ltd. into Anchiano Therapeutics Ltd. effective on March 16, 2021 (the "Merger"). Reflects a 4:1 reverse stock split of Ordinary Shares and increase in the number of Ordinary Shares per ADS from 5 to 20 effected by the Issuer in connection with the closing of the Merger.
F2: Each American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares of the Issuer.
F3: These securities are held of record by Rivendell Investments 2017-9 LLC. The Reporting Person is the beneficial owner of Rivendell Investments 2017-9 LLC and has sole voting and investment power over the securities held by Rivendell Investments 2017-9 LLC.